GRAIL’s Holy Grail
GRAIL (Menlo Park, CA) may soon release its cancer diagnostic “Galleri” which can confirm fifty different cancers from a DNA fragment found in a blood test. “At this year’s annual meeting of the American Society of Clinical Oncology, Grail presented its first results from an interventional study of more than 6,600 participants, tracking the Galleri test’s use in real-world clinical settings, such as the steps oncologists take after the diagnostic returns a positive result. The study pegged Galleri’s total positive predictive value at 44.6% and found that it accurately determined the cancer’s origin site 96.3% of the time. “Most importantly, it can detect cancers that have no recommended screening tests today, and more than two-thirds of cancers go unscreened for this reason . . .” MORE
Image Credit: pixabay